American Vanguard Corporation — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2012. Unaudited consolidated results; amounts are in millions of dollars unless stated otherwise.
Business context and financial performance
The company reports one business segment, selling crop-protection and non-crop products. Second-quarter performance improved year over year, led by insecticides and higher gross margins. First-half results also benefited from strong early-season demand and favorable growing conditions, although drought affected some regions.
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Net sales | $84.8 | $80.1 | $172.1 | $146.1 |
| Gross profit | $38.3 | $31.7 | $75.7 | $58.6 |
| Gross margin | 45% | 40% | 44% | 40% |
| Operating income | $14.2 | $10.7 | $28.6 | $19.9 |
| Net income | $8.7 | $6.0 | $17.5 | $11.0 |
| Diluted earnings per share | $0.30 | $0.22 | $0.61 | $0.40 |
Q2 sales grew 6% and net income 46%; first-half sales grew 18% and net income 59%. Management attributed margin improvement mainly to insecticide price increases, product mix, and strong demand for higher-margin products. Operating expenses increased to $24.1 million in Q2 (from $21.0 million) and $47.1 million in the first half (from $38.7 million), including higher incentive compensation, research and regulatory costs, and freight.
Sales trends and material changes
- Q2 insecticide sales increased 32% to $45.4 million; first-half sales rose 38% to $101.3 million. Drivers included demand for granular soil insecticides, increased peanut acres, sugar-cane demand, and cotton channel restocking.
- Q2 herbicide sales fell 29% to $13.7 million, primarily because the company had largely sold through its Impact corn herbicide inventory. First-half herbicide sales were approximately flat overall; Dacthal and soil fumigants partly offset Impact’s decline.
- Q2 sales in “other” products fell 17% to $16.2 million, mainly because limited supply constrained Folex cotton harvest-aid sales. Non-crop sales rose 40% to $9.5 million, helped by mosquito adulticide demand.
- First-half export sales increased 51% year over year. Freight, delivery and warehousing costs rose to 6.2% of sales from 5.3%.
Cash flow, liquidity and debt
- Six-month operating cash flow was $36.7 million, versus $2.3 million in the prior-year period. The reported increase included a $30.9 million rise in other liabilities, predominantly customer program accruals, as well as higher earnings. Receivables and inventory used $3.9 million and $8.9 million, respectively.
- Cash was $48.0 million at June 30, 2012, up from $35.1 million at year-end. Capital expenditures were $13.1 million, mainly to expand manufacturing capacity. Financing activities used $10.8 million, including debt and acquisition-note payments and $1.4 million of dividends.
- Total debt was $56.1 million, down from $66.4 million at December 31, 2011; the company had no working-capital revolver borrowings. Cash exceeded reported debt by approximately $8.0 million. Current assets were $206.1 million and current liabilities $104.1 million.
- The company reported compliance with all credit-facility covenants and stated it had capacity to borrow up to $75 million under the facility, subject to its terms and covenants. Substantially all assets are pledged as collateral. On July 3, the facility was amended to permit up to $2 million of investment in foreign subsidiaries.
Outlook, commentary and risks
- No specific earnings or revenue guidance was provided. Management said a standalone Folex production unit was nearing completion and expected to help meet customer demand in the second half of 2012.
- Management cited risks from weather, product demand and acceptance, regulation, competition and pricing, foreign exchange, product development, supply and capacity constraints, and capital availability. It reported no material changes to the risk factors in the 2011 Form 10-K.
- PCNB registrations had been approved for major commercial uses after a prior EPA stop-sale order was vacated. The company held $20.0 million of related inventory and $4.9 million of associated intangible assets; it could not conclude that a loss was probable or reasonably estimable.
- Approximately 100 DBCP-related lawsuits were disclosed. AMVAC was dismissed with prejudice from one California action; other matters remained pending or were newly filed. The company said losses in the discussed cases were not then probable or reasonably estimable and recorded no loss contingency.
- On July 6, the company announced formation of Netherlands-based operating and holding entities to support ex-U.S. sales and operations. A 10% change in foreign currencies was stated to have an immaterial effect on financial position and cash flows.
Important facts for investors to verify
- Whether strong insecticide demand and improved gross margins continue, given the seasonal nature of sales and mixed trends across product categories.
- Progress on Folex production capacity and whether it resolves supply constraints; also verify the timing and cost of manufacturing expansion.
- The composition and timing of the $30.9 million increase in other liabilities and customer program accruals, and the cash impact of subsequent program payments.
- Developments in PCNB labeling and disposition of existing stocks, and any change in the assessed exposure of related inventory and intangible assets.
- Developments in DBCP litigation, including the pending and newly filed cases, and whether any loss becomes estimable or requires accrual.